InnoCan Pharma Corporation announced that it has inaugurated its first and new drug research and development lab at Biohouse Labs at Hadassah Medical Center in Jerusalem to accelerate the Company's liposome Platform Technology (LPT) development. The Company's development program is focused on improving and optimizing LPT characterization methods and upscaling capabilities. The company believes that upscaling production capabilities will enable company to move forward with the planned experiments and may serve the basis for tech transfer for GMP production- which is a basic need to reaching clinical human trials.

A staff of 6 people (scientists and scientific assistants) are currently working on the accelerated development of the LPT technology. The company previously announced that prior studies of the prolonged release of cannabidiol (CBD) from the liposomes injected subcutaneously to dogs showed continuous and significant blood concentrations of CBD over at least six weeks after a single administration. These results are a significant advancement in the development of the technology, demonstrating the advantages of LPT in dogs, which may serve as a good prediction to the behavior of LPT in humans.